| 本文已被：浏览 426次 下载 285次 |
码上扫一扫！ |
| 泛福舒防治儿童反复呼吸道感染成本-效益分析 |
| 曹旺1,刘水2,王强3,蔡彦蓉3,尉耘翠1,贾露露1,王晓玲1 |
|
|
| (1. 国家儿童医学中心,首都医科大学附属北京儿童医院,北京 100045;2. 应急总医院,北京 100028;3. 北京普瑞快思医药咨询有限公司,北京 100025) |
|
| 摘要: |
| 目的:评估细菌溶解产物(泛福舒)联合常规治疗预防儿童反复呼吸道感染(RRTI)的经济性。方法:采用成本-效益分析
法,计算RRTI 患儿加用泛福舒后的增量成本和增量效益,从而计算净效益。采用专家访谈和问卷调研,收集相关的成本和费
用参数。结果:共计访谈8 名临床医师,收集相关参数进行分析。结果显示,在6 个月随访期内,如果使用1 个疗程泛福舒,能
减少1. 96 次RRTI,增量成本为199. 59 元,增量效益为4 601. 98 元,净效益为4 402. 39 元,即每增加1 元的投入,将获得增量净
效益22. 06 元。敏感性分析显示结果稳定。结论:在常规治疗基础上加用泛福舒对防治儿童RRTI 具有经济性,但未来仍需要
真实世界数据补充和验证相关结论。 |
| 关键词: 细菌溶解产物 反复呼吸道感染 儿童 成本效益分析 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2023.05.003 |
|
| 基金项目:国家呼吸系统疾病临床医学研究中心呼吸专项,编号HXZX-202107;首都医科大学附属北京儿童医院管理课题,编号YGLQ2022001。 |
|
| Cost-Benefit Analysis of Bacterial Lysates for Recurrent Respiratory Tract Infections in Children |
| Cao Wang1, Liu Shui2, Wang Qiang3, Cai Yanrong3, Yu Yuncui1, Jia Lulu1, Wang Xiaoling1 |
| (1. Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; 2. Emergency General Hospital,Beijing 100028, China; 3. Beijing Prescription Consultant Ltd. , Beijing 100025, China) |
| Abstract: |
| Objective: To evaluate the economic feasibility of using bacterial lysates (Broncho-Vaxom) combined with conventional
therapy for treating recurrent respiratory tract infections (RRTI) in children. Methods: Cost-benefit analysis was used to calculate the
net benefit by comparing the incremental cost and benefit in RRTI children after using bacterial lysates. Expert interviews and
questionnaires were conducted for collecting relevant cost and expense parameters. Results: A total of 8 clinicians received the interview
and completed the questionnaire, and the collected parameters were analyzed. The results showed that using one course of Broncho-
Vaxom could reduce 1. 96 times of RRTI during 6-month follow-up. The incremental cost was about 199. 59 yuan, while with an
incremental benefit of 4,601. 98 yuan, which achieved 4,402. 39 yuan in net benefit. This means that for every additional yuan
invested, a net benefit of 22. 06 yuan can be obtained. Sensitivity analysis also showed the robustness and reliability. Conclusion: The
combined use of bacterial lysates has cost-benefit for the prevention and treatment of RRTI in children. More real-world evidence and
data still be needed to supplement and validate the conclusions in the future. |
| Key words: bacterial lysate recurrent respiratory tract infection children cost-benefit analysis |
